Leerink Partnrs Issues Optimistic Forecast for MIRM Earnings

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) – Analysts at Leerink Partnrs boosted their Q3 2025 earnings estimates for Mirum Pharmaceuticals in a research note issued on Wednesday, October 15th. Leerink Partnrs analyst M. Foroohar now forecasts that the company will post earnings of ($0.12) per share for the quarter, up from their previous forecast of ($0.18). The consensus estimate for Mirum Pharmaceuticals’ current full-year earnings is ($1.43) per share. Leerink Partnrs also issued estimates for Mirum Pharmaceuticals’ Q4 2025 earnings at ($0.17) EPS and FY2025 earnings at ($0.70) EPS.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its earnings results on Wednesday, August 6th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.19. Mirum Pharmaceuticals had a negative net margin of 13.65% and a negative return on equity of 24.76%. The business had revenue of $127.79 million during the quarter, compared to analyst estimates of $107.91 million. During the same period in the previous year, the business posted ($0.52) earnings per share. Mirum Pharmaceuticals’s revenue for the quarter was up 64.1% on a year-over-year basis.

Several other brokerages have also issued reports on MIRM. TD Cowen upgraded shares of Mirum Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, September 25th. Morgan Stanley lifted their target price on shares of Mirum Pharmaceuticals from $75.00 to $81.00 and gave the company an “overweight” rating in a research report on Thursday. Cowen began coverage on shares of Mirum Pharmaceuticals in a report on Wednesday, September 24th. They issued a “buy” rating for the company. JMP Securities set a $81.00 price objective on shares of Mirum Pharmaceuticals and gave the stock a “market outperform” rating in a report on Thursday, August 7th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Mirum Pharmaceuticals from $53.00 to $77.00 and gave the stock an “overweight” rating in a report on Friday, September 12th. Two analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $79.70.

Mirum Pharmaceuticals Trading Down 1.2%

Shares of Mirum Pharmaceuticals stock opened at $73.53 on Friday. Mirum Pharmaceuticals has a 1 year low of $36.88 and a 1 year high of $78.54. The firm has a market cap of $3.69 billion, a PE ratio of -60.77 and a beta of 0.81. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.13 and a quick ratio of 2.97. The company has a 50 day simple moving average of $72.58 and a two-hundred day simple moving average of $55.70.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the stock. CWM LLC lifted its position in shares of Mirum Pharmaceuticals by 259.4% in the 1st quarter. CWM LLC now owns 593 shares of the company’s stock worth $27,000 after purchasing an additional 428 shares during the period. Comerica Bank lifted its position in shares of Mirum Pharmaceuticals by 45.1% in the 1st quarter. Comerica Bank now owns 895 shares of the company’s stock worth $40,000 after purchasing an additional 278 shares during the period. Osaic Holdings Inc. lifted its position in shares of Mirum Pharmaceuticals by 46.5% in the 2nd quarter. Osaic Holdings Inc. now owns 1,106 shares of the company’s stock worth $56,000 after purchasing an additional 351 shares during the period. Quarry LP purchased a new stake in shares of Mirum Pharmaceuticals in the 1st quarter worth about $56,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Mirum Pharmaceuticals by 14.9% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,914 shares of the company’s stock worth $97,000 after purchasing an additional 248 shares during the period.

Insider Activity

In other news, CFO Eric Bjerkholt sold 9,578 shares of the firm’s stock in a transaction dated Friday, September 12th. The shares were sold at an average price of $76.01, for a total value of $728,023.78. Following the completion of the sale, the chief financial officer directly owned 39,945 shares of the company’s stock, valued at approximately $3,036,219.45. This trade represents a 19.34% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Laura Brege sold 17,000 shares of the firm’s stock in a transaction dated Thursday, September 11th. The stock was sold at an average price of $74.40, for a total transaction of $1,264,800.00. Following the completion of the sale, the director directly owned 15,703 shares of the company’s stock, valued at approximately $1,168,303.20. This represents a 51.98% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 116,578 shares of company stock valued at $7,262,824 in the last three months. Corporate insiders own 14.36% of the company’s stock.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.